Evidence map›Paper›PMID 42792703›Full record

ReviewBiomedicines2026

Beyond m

Zongchen Hou, Diaoyi Tan, Zhiyong Xiong, Daojia Miao

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biomedicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zongchen HouDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.ORCID 0009-0009-3565-9933
Diaoyi TanDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Zhiyong XiongDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Daojia MiaoDepartment of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.ORCID 0000-0002-7780-1282

Funding

Huazhong University of Science and Technology 02.05.22030029National Natural Science Foundation of China 82202911National Natural Science Foundation of China 82300786Science and Technology Department of Hubei Province 2023AFB210Science and Technology Department of Hubei Province 2024AFB640
6 · The paper itself

Abstract

Renal cell carcinoma (RCC) comprises molecularly diverse tumor subtypes. This diversity is reflected in distinct and adaptable gene-expression programs that enable tumor cells to reprogram metabolism and survive therapeutic pressure. By regulating RNA processing, export, stability, decay, and translation, messenger RNA (mRNA) modifications may help shape these programs. Examining mRNA modifications is therefore important for understanding metabolic adaptation and treatment resistance in RCC. This narrative review focuses on RCC studies of N6-methyladenosine (m

Indexed as

epitranscriptomicsmRNA modificationrenal cell carcinomatherapeutic resistance

Identifiers

PMID42792703
PMCPMC13604773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.